Josep M. Llovet
约瑟普·略维特
MD, PhD
Professor of Medicine and Director, Liver Cancer Program医学教授及肝癌项目主任
👥Biography 个人简介
Josep Llovet is a globally recognized leader in HCC research, instrumental in the pivotal SHARP trial that established sorafenib as the first systemic therapy for advanced HCC. His molecular classification of HCC subtypes has guided biomarker-driven treatment strategies worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Sorafenib in HCC
Led the landmark SHARP trial demonstrating sorafenib's survival benefit in advanced HCC, establishing the first approved systemic therapy for this disease.
HCC Molecular Classification
Developed a molecular subclass framework for HCC that underpins current biomarker-guided therapeutic strategies and clinical trial design.
BCLC Staging System
Co-developed the Barcelona Clinic Liver Cancer (BCLC) staging system, the most widely adopted HCC staging and treatment allocation framework globally.
Representative Works 代表性著作
Sorafenib in advanced hepatocellular carcinoma (SHARP trial)
New England Journal of Medicine (2008)
Landmark RCT showing sorafenib improved overall survival in advanced HCC, establishing the standard of care for a decade.
Molecular classification and novel targets in hepatocellular carcinoma
Nature Reviews Cancer (2022)
Comprehensive review of HCC molecular subtypes and emerging therapeutic vulnerabilities guiding next-generation trials.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 约瑟普·略维特 的研究动态
Follow Josep M. Llovet's research updates
留下邮箱，当我们发布与 Josep M. Llovet（Icahn School of Medicine at Mount Sinai）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment